TY - JOUR
T1 - Targeting PD-I/PD-LI in lung cancer
T2 - Current perspectives
AU - González-Cao, María
AU - Karachaliou, Niki
AU - Viteri, Santiago
AU - Morales-Espinosa, Daniela
AU - Teixidó, Cristina
AU - Ruiz, Jesús Sánchez
AU - Molina-Vila, Miquel Ángel
AU - Santarpia, Mariacarmela
AU - Rosell, Rafael
PY - 2015/7/31
Y1 - 2015/7/31
N2 - Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/ PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I-III trials with anti-PD-1/PD-L1 antibodies in nonsmall-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.
AB - Increased understanding of tumor immunology has led to the development of effective immunotherapy treatments. One of the most important advances in this field has been due to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/ PD-L1 antibodies are currently in advanced phases of clinical development for several tumors, including lung cancer. Results from Phase I-III trials with anti-PD-1/PD-L1 antibodies in nonsmall-cell lung cancer have demonstrated response rates of around 20% (range, 16%–50%). More importantly, responses are long-lasting (median duration of response, 18 months) and fast (50% of responses are detected at time of first tumor evaluation) with very low grade 3–4 toxicity (less than 5%). Recently, the anti-PD-1 antibody pembrolizumab received US Food and Drug Administration (FDA) breakthrough therapy designation for treatment of non-small-cell lung cancer, supported by data from a Phase Ib trial. Another anti-PD-1 antibody, nivolumab, has also been approved for lung cancer based on survival advantage demonstrated in recently released data from a Phase III trial in squamous cell lung cancer.
KW - Cancer
KW - Checkpoint inhibitors
KW - Immunoncology
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84942319348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942319348&partnerID=8YFLogxK
U2 - 10.2147/LCTT.S55176
DO - 10.2147/LCTT.S55176
M3 - Article
AN - SCOPUS:84942319348
VL - 6
SP - 55
EP - 70
JO - Lung Cancer: Targets and Therapy
JF - Lung Cancer: Targets and Therapy
SN - 1179-2728
ER -